How Sienna Cancer Diagnostics are translating telomerase into a cancer biomarker.




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: How Sienna Cancer Diagnostics are translating telomerase into a cancer biomarker.
Released on: December 15, 2015. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Cliff Holloway, CEO to Sienna Cancer Diagnostics, discusses the development and commercialisation of SCE-A7, the first telomerase detection product.
  • Summary
  • Transcript
  • Participants
  • Company
Cliff Holloway, CEO to Sienna Cancer Diagnostics, discusses the development and commercialisation of SCE-A7, the first telomerase detection product.
Cliff Holloway, CEO to Sienna Cancer Diagnostics, discusses the development and commercialisation of SCE-A7, the first telomerase detection product.
Dr. Cliff Holloway brings over 25 years of biopharmaceutical and healthcare related experience to Sienna, including development and commercialisation of emerging technologies and drug products, as well as marketing, licensing, M&A, corporate financing and operations management. Most recently, he was CEO and Managing Director of Immune System Therapeutics Ltd., a public unlisted company developing biologic therapies for blood cancers. Prior to his role at IST, he held the position of Managing Director at Biosceptre International Ltd. and VP of Business Development at Arana Therapeutics Ltd. which was acquired by US based Cephalon Inc. (now Teva) in 2009. He is currently a director of a biotech focused seed fund, Newstar Ventures. Cliff holds a Bachelor of Pharmacy and a Ph.D in medicinal chemistry from the University of Nottingham, UK.
Sienna is a biotechnology company focussed on the development and commercialisation of novel IVD (in vitro diagnostic) tests. Sienna manufactures individual component products for research institutions and pathology laboratories to use in research or in their own laboratory developed tests. Sienna registered their first product with the FDA in 2014, the Anti-hTERT antibody (SCD-A7).